Developing a first in class therapeutic platform that rescues immune function and drives tumor clearance in advanced cancer patients

Synthis Therapeutics is an early-stage biotech company dedicated to the innovation of targeted therapies that harnesses the power of patients’ own immune system to eliminate metastatic cancer. Our novel therapeutic platform evolved from an idea to develop safer and more efficacious therapies that eliminate one of the most immunosuppressive pathways in virtually all cancers, known as TGF-β. By developing therapies that selectively target the immunosuppressive arm of the TGF-β pathway, we can safely drive efficacy and patient survival